Metabolomics in Breast Cancer: From Biomarker Discovery to Personalized Medicine

Breast cancer (BC) is a highly heterogeneous disease with distinct molecular subtypes, each exhibiting unique metabolic adaptations that drive tumor progression and therapy resistance. Metabolomics has emerged as a powerful tool for understanding cancer metabolism and identifying clinically relevant biomarkers guiding personalized therapeutic strategies. Advances in analytical techniques such as mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy have enabled the identification of metabolic alterations associated with BC initiation, progression, and treatment response (dysregulated glycolysis, lipid metabolism, amino acid utilization, and redox homeostasis). This review aims to provide a comprehensive overview of the role of metabolomics in BC research, focusing on its applications in identifying metabolic biomarkers for early diagnosis, prognosis, and treatment response. It underscores how metabolomic profiling can unravel the metabolic adaptations of different BC subtypes, offering insights into tumor biology and mechanisms of therapy resistance. Ultimately, it highlights the promise of metabolomics in driving biomarker-guided diagnostics and the development of metabolically informed, personalized therapeutic strategies in the era of precision medicine.